Clinicians treating schizophrenia routinely employ high doses and/or antipsychotic switching to achieve response. However, little is actually known regarding the value of these interventions in early schizophrenia. Data were gathered from a treatment algorithm implemented in patients with first-episode schizophrenia that employs two antipsychotic trials at increasing doses before clozapine. Patients were initially treated with either olanzapine or risperidone across three dose ranges, (low, full, high), and in the case of suboptimal response were switched to the alternate antipsychotic. We were interested in the value of (a) high dose treatment and (b) antipsychotic switching. A total of 244 patients were evaluated, with 74.5% (184/244) responsive to Trial 1, and only 16.7% (10/60) responsive to Trial 2. Percentage of response for subjects switched from olanzapine to risperidone was 4.0% (1/25) vs. 25.7% (9/35) for those switched from risperidone to olanzapine. High doses yielded a 15.5% response (14.6% for risperidone vs. 16.7% for olanzapine).The present findings concur with other research indicating that response rate to the initial antipsychotic trial in first-episode schizophrenia is robust; thereafter it declines notably....Continue Reading
Risperidone, 2 mg/day vs. 4 mg/day, in first-episode, acutely psychotic patients: treatment efficacy and effects on fine motor functioning
Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders
Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders
Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis
Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment
Switching to risperidone after unsuccessful treatment of olanzapine in the first-episode schizophrenia: an open trial
A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis
Switching to olanzapine after unsuccessful treatment with risperidone during the first episode of schizophrenia: an open-label trial
Remission and relapse in the outpatient care of schizophrenia: three-year results from the Schizophrenia Outpatient Health Outcomes study
Symptomatic remission in previously untreated patients with schizophrenia: 2-year results from the SOHO study
Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study
Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST)
Antipsychotic drug treatment in first-episode psychosis: should patients be switched to a different antipsychotic drug after 2, 4, or 6 weeks of nonresponse?
Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis
An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis
Haloperidol versus second-generation antipsychotics in the long-term treatment of schizophrenia: a 4-year follow-up naturalistic study
Duration of untreated psychosis: relationship with baseline characteristics and three-year outcome in first-episode psychosis
Effectiveness of antipsychotic maintenance therapy with quetiapine in comparison with risperidone and olanzapine in routine schizophrenia treatment: results of a prospective observational trial
Comparative effectiveness of atypical antipsychotics in schizophrenia: what have real-world trials taught us?
Strategies for Early Non-response to Antipsychotic Drugs in the Treatment of Acute-phase Schizophrenia
Correlates of Clozapine Use after a First Episode of Schizophrenia: Results From a Long-term Prospective Study
Current Data on and Clinical Insights into the Treatment of First Episode Nonaffective Psychosis: A Comprehensive Review
Clozapine as a first- or second-line treatment in schizophrenia: a systematic review and meta-analysis
Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology.
Plasma monoamines change under dopamine supersensitivity psychosis in patients with schizophrenia: A comparison with first-episode psychosis.
Presynaptic Dopamine Capacity in Patients with Treatment-Resistant Schizophrenia Taking Clozapine: An [18 F]DOPA PET Study
First-episode psychosis in treatment-resistant schizophrenia: a cross-sectional study of a long-term follow-up cohort
Switching and augmentation strategies for antipsychotic medications in acute-phase schizophrenia: latest evidence and place in therapy
The Complex Relationship between Antipsychotic-Induced Weight Gain and Therapeutic Benefits: A Systematic Review and Implications for Treatment
The impact of a change in prescribing policy on antipsychotic prescribing in a general adult psychiatric hospital
Switching to Lurasidone following 12 months of treatment with Risperidone: results of a 6-month, open-label study
Serum estradiol as a blood-based biomarker predicting hormonal treatment outcomes in women with schizophrenia.
Treatment patterns and appropriateness of antipsychotic prescriptions in patients with schizophrenia.
Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here